Table 1 Characteristics of the study population and follow up

Age (years, median/range)

61 (21–87)

Gender (F/M)

432/364

Body Mass Index (kg/m², median, range IQR)

24.23 (21.9-27.18)

Follow up (weeks, median, range IQR)

35.14 (23–55.4)

Follow up completed (n° pts/total pts)

535/796

Length of use (weeks, median, range IQR)

22.71 (10.1-41.9)

Time of in-situ permanence (weeks, median, range IQR)

33.71 (15.71-57)

Pancreatic cancer (n° pts)

20

Colon/rectal cancer

218

Gastric cancer

67

Oesophageal cancer

102

Lymphoma

29

Breast cancer

127

Brain cancer

14

Head and neck cancer

33

Sarcoma

48

Liver cancer

15

Lung cancer

36

Ovarian cancer

38

Melanoma

13

Urothelial cancer

6

Teratoma

5

Other miscellaneous

25

White blood cells count (cells ×10⁹/L, median, range IQR)

6 (1.98-8.77)

Hb (g/L, median, range IQR)

12 (10–13)

Platelets (cells × 10⁹/L, median, range IQR)

276 (223–341.5)

PT (%, prothrombin time, median, range IQR)

88 (75–100)

PTT (sec, partial thromboplastin time, median, range IQR)

28 (26–30)

INR (international normalized ratio, median, range IQR)

1,00 (0.5-1.12)